Bayer

Contact Us

Congress Library

American Society of Nephrology Kidney Week 2024

Presentations

The FINEARTS-HF Trial The FINEARTS-HF Trial

Finnian McCausland

Finerenone and Kidney Outcomes in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial

Click to access
A FIDELITY analysis A FIDELITY analysis

Ajay Singh

Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease by SGLT-2i And GLP-1RA Use: A FIDELITY Analysis

Click to access

Posters

A CKD Stage Subgroup Analysis from The FOUNTAIN Platform A CKD Stage Subgroup Analysis from The FOUNTAIN Platform

Csaba Kovesdy

UACR Reduction in People with CKD and T2D Initiating Finerenone – A CKD Stage Subgroup Analysis from The FOUNTAIN Platform

Click to access
American College of Cardiology American College of Cardiology

Csaba Kovesdy

UACR Reduction in People with CKD and T2D Initiating Finerenone – A Comedication Subgroup Analysis from The FOUNTAIN Platform

Click to access
An Interim Analysis of the Prospective, Real-World, Observational FINE-REAL Study An Interim Analysis of the Prospective, Real-World, Observational FINE-REAL Study

Christoph Wanner

Dosing, Treatment Patterns, and Safety of Finerenone Use in Routine Care: An Interim Analysis of the Prospective, Real-World, Observational FINE-REAL Study

Click to access
American College of Cardiology American College of Cardiology

Zihe Zheng

Utilization of Non-Steroidal Mineralocorticoid Receptor Antagonist (MRA) Finerenone with or without Prior Steroidal MRA

Click to access
An Interim Analysis of the Prospective, Real-World, Observational FINE-REAL Study An Interim Analysis of the Prospective, Real-World, Observational FINE-REAL Study

Zihe Zheng

Utilization of Guideline-Directed Medical Therapies in Finerenone Users

Click to access

Follow Us

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

Copyright © 2024 Bayer

Bayer and the Bayer Cross are registered trademarks of Bayer.

sitemap